Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC.

Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.

PMID:
31221619
2.

Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin-an Intracerebral Microdialysis Study in Sprague-Dawley Rats.

Zhang Y, Bowman K, Maleski J, Diamond S, Yeleswaram S.

Drug Metab Dispos. 2019 Jul;47(7):710-714. doi: 10.1124/dmd.118.084053. Epub 2019 Apr 22.

PMID:
31010933
3.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS.

J Immunother Cancer. 2019 Mar 20;7(1):80. doi: 10.1186/s40425-019-0562-8.

4.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF.

J Clin Oncol. 2018 Sep 28:JCO2018789602. doi: 10.1200/JCO.2018.78.9602. [Epub ahead of print]

5.

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.

Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA, Shi JG, Liu X, Newton RC, Zhao Y, Maleski J, Leopold L, Schilder RJ.

Gynecol Oncol. 2017 Sep;146(3):484-490. doi: 10.1016/j.ygyno.2017.07.005. Epub 2017 Jul 8.

PMID:
28698009
6.

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF.

Clin Cancer Res. 2017 Jul 1;23(13):3269-3276. doi: 10.1158/1078-0432.CCR-16-2272. Epub 2017 Jan 4.

7.

Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.

Shi JG, Bowman KJ, Chen X, Maleski J, Leopold L, Yeleswaram S.

J Clin Pharmacol. 2017 Jun;57(6):720-729. doi: 10.1002/jcph.855. Epub 2016 Dec 19.

PMID:
27990653
8.

Evidence supporting the role of calpain in the α-processing of amyloid-β precursor protein.

Nguyen HT, Sawmiller DR, Wu Q, Maleski JJ, Chen M.

Biochem Biophys Res Commun. 2012 Apr 13;420(3):530-5. doi: 10.1016/j.bbrc.2012.03.026. Epub 2012 Apr 4.

PMID:
22480599
9.

Scientific truth or false hope? Understanding Alzheimer's disease from an aging perspective.

Chen M, Maleski JJ, Sawmiller DR.

J Alzheimers Dis. 2011;24(1):3-10. doi: 10.3233/JAD-2010-101638. Review.

PMID:
21178284
10.

Atrial natriuretic peptide production and natriuretic peptide receptors in the human uterus and their effect on myometrial relaxation.

Cootauco AC, Murphy JD, Maleski J, Blakemore KJ, Slodzinski MK.

Am J Obstet Gynecol. 2008 Oct;199(4):429.e1-6. doi: 10.1016/j.ajog.2008.05.019. Epub 2008 Aug 8.

PMID:
18691685

Supplemental Content

Loading ...
Support Center